Covered recipient · General Payments record
KEVIN YIP
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
General Payments · PY2021–2024
$820.33
- Reported across 18 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $564.24 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $258.73 | 6 |
| GlaxoSmithKline, LLC. | $161.66 | 3 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $30.26 | 1 |
| Exact Sciences Corporation | $27.43 | 1 |
| Janssen Pharmaceuticals, Inc | $26.06 | 1 |
| Teva Pharmaceuticals USA, Inc. | $23.22 | 1 |
| Shionogi Inc | $22.32 | 1 |
| Janssen Biotech, Inc. | $14.56 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $17.13 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106376764 | CMS |
| ABBVIE INC. | $16.76 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106376766 | CMS |
| ABBVIE INC. | $24.86 | 05/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106376768 | CMS |
| ABBVIE INC. | $26.44 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106376770 | CMS |
| ABBVIE INC. | $25.49 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106376772 | CMS |
| ABBVIE INC. | $148.05 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106376774 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $30.26 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117860183 | CMS |
| Exact Sciences Corporation | $27.43 | 10/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114956229 | CMS |
| GlaxoSmithKline, LLC. | $124.98 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115907439 | CMS |
| GlaxoSmithKline, LLC. | $30.45 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116473691 | CMS |
| GlaxoSmithKline, LLC. | $6.23 | 12/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116578040 | CMS |
| Janssen Biotech, Inc. | $14.56 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078408435 | CMS |
| Janssen Pharmaceuticals, Inc | $26.06 | 03/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078106622 | CMS |
| Shionogi Inc | $22.32 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154342276 | CMS |
| Teva Pharmaceuticals USA, Inc. | $23.22 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151566351 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2021 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.